Abstract
According to the two currently most popular biological hypotheses, schizophrenic symptoms result from a hyperactivity in dopaminergic neurotransmission or from a hypoactivity in GABAergic neurotransmission. Since diazepam is known to reduce dopamine release and to potentiate GABA, the possible beneficial effects of diazepam were tested in ten hospitalized chronic schizophrenic patients who were resistant to standard neuroleptic treatment. High doses of diazepam, up to 200 mg/day initially, but smaller maintenance doses (less than 55 mg/day diazepam in eight of the ten patients) were added to the previous neuroleptic medication of these patients. The diazepam dose was adjusted daily to avoid oversedation. The effects of diazepam treatment on the mental status were assessed weekly for 12 weeks by the Brief Psychiatric Rating Scale (BPRS), the physician's Clinical Global Impressions Scale (CGI), and the Psychotic inpatient Profile Scale (PIP). For additional documentation, videotapes of mental status interviews were obtained at baseline and during diazepam treatment. These videotapes were rated blind by an independent psychiatrist. The addition of diazepam produced a marked improvement in three, a moderate improvent in four, a mild improvement in one and no change in two of the ten patients. Four of the ten patients were so much improved that they were discharged from the hospital. No side effects were noted, except for one patient who became confused and disoriented on 160 mg diazepam/day. Oversedation was avoided in the other patients, whose maximum daily dose of diazepam was 100 mg or higher, by reducing the diazepam dose within 1 week after the maximum daily dose was reached. It is concluded that diazepam may be of use in the treatment of schizophrenia and that further controlled clinical studies are warranted.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Andén NE (1977) Effects of γ-hydroxybutyric acid, baclofen, aminoxyacetic acid, and apomorphine on dopamine turnover in corpus striatum and limbic system. In: Costa E, Gessa GL (eds) Nonstriatal dopaminergic neurons. Raven, New York, pp 495–499
Andén NE, Wachtel H (1978) Some effects of GABA and GABA-like drugs on central catecholamine mechanisms. In: Garattini S, Pujol JF, Samanin R (eds) Interactions between putative neurotransmitters in the brain. Raven, New York, pp 161–173
Beckmann H, Haas S (1980) High-dose diazepam in schizophrenia. Psychopharmacology 71:79–92
Carlsson A (1978) Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 135:164–173
Carlsson A, Biswas B (1978) Effect of GABA administered intracerebroventricularly or intraperitoneally on brain monoamines and locomotor activity. In: Garattini S, Pujol JF, Samanin R (eds) Interactions between putative neurotransmitters in the brain. Raven, New York, pp 305–315
Cheramy A, Nieoullon A, Glowinski J (1978) GABAergic processes involved in the control of dopamine release from nigrostriatal dopaminergic neurons in the cat. Eur J Pharmacol 48:281–295
Costa E, Guidotti A (1979) Molecular mechanisms in the receptor action of benzodiazepines. Annu Rev Pharmacol Toxicol 19:531–545
Christensen AV, Arnt J, Scheel-Krüger J (1979) Decreased antistereotypic effect of neuroleptics after additional treatment with a benzodiazepine, a GABA agonist or an anticholinergic compound. Life Sci 24:1395–1402
Davis JM, Cole JO (1975) Antipsychotic drugs. In: Arieti, S, Freedman DX, Dyrud JE (eds) American handbook of psychiatry, vol 5. Basic Books New York, pp 441–475
Davis KL, Hollister LE, Berger PA (1976) Baclofen in schizophrenia. Lancet I:1245
Fuxe K, Andersson K, Ogren SO, Perez De La Mora M Schwarcz R, Hokfelt T, Encroth P, Gustafsson JA, Skett P (1978) GABA neurons and their interaction with monoamine neurons: An anatomical, pharmacological and functional analysis. In: Krogsgaard-Larsen P, Scheel-Krüger J, Kofod H (eds) GABA-neurotransmitters. Munksgaard, Copenhagen, pp 74–94
Guy W (1976) ECDEU assessment manual for psychopharmacology. US Department of Health, Education and Welfare Publication 76–338, Washington DC
Jimerson DC, Van Kammen DP, Post RM, Docherty JP, Bunney Jr WE (1982) Diazepam in schizophrenia: A preliminary double-blind trial. Am J Psychiatry 139:489–491
Klein DF, Davis JM (1969) Diagnosis and drug treatment of psychiatric disorders. Williams Wilkins, Baltimore, p 55
Lautin A, Angrist B, Stanley M, Gershon S, Heckl K, Karobath M (1980) Sodium valproate in schizophrenia: Some biochemical correlates. Br J Psychiatry 137:240–244
Lorr M, Vestre ND (1969) The psychotic inpatient profile: A nurse's observation scale. J Clin Psychol 25:137–140
Meltzer HY, Stahl SM (1976) The dopamine hypothesis of schizophrenia: A review. Schizophr Bull 2:19–76
Nestoros JN (1980) Benzodiazepines in schizophrenia.: A need for reassessment. Int Pharmacopsychiatry 15:171–179
Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:799–812
Rastogi RB, Lapierre YD, Singhal RL, Nair NPV (1980) Evidence for the involvement of dopamine in the action of diazepam: Potentiation of haloperidol and chlorpromazine action in the brain. Adv Biochem Psychopharmacol 24:283–289
Roberts E (1972) Prospects for research on schizophrenia: An hypothesis suggesting that there is a defect in the GABA system in schizophrenia. Neurosci Res Program Bull 10:468–482
Roberts E (1976) Dislnhibition as an organizing principle in the nervous system: The role of the GABA system Application to neurologic and psychiatric disorders. In: Roberts E, Chase TN, Tower DB (eds) GABA in nervous system function. Raven, New York, pp 515–539
Simpson GM, Branchey MH, Shrivastava RK (1979) Baclofen in schizophrenia. Lancet I:966–967
Snyder SH (1972) Catecholamines in the brain as mediators of amphetamine psychosis. Arch Gen Psychiatry 27:169–179
Spitzer RL, Endicott J, Robins E (1978) Research Diagnostic Criteria (RDC) for a selected group of functional disorders. New York Psychiatric Institute, New York
Tamminga CA, Crayton JW, Chase TN (1978) Muscimol: GABA agonist therapy in schizophrenia. Am J Psychiatry 135:746–747
Van Kammen DP (1977) γ-Aminobutyric acid (GABA) and the dopamine hypothesis of schizophrenia. Am J Psychiatry 134:138–143
Wood PL (1982) Achons of GABAergic agents on dopamine metabolism in the nigrostriatal pathway of the rat. J Pharmacol Exp Ther 222:674–679
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nestoros, J.N., Nair, N.P.V., Pulman, J.R. et al. High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients. Psychopharmacology 81, 42–47 (1983). https://doi.org/10.1007/BF00439272
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00439272